Association of pretreatment (preTx) tumor characteristics and clinical outcomes following second-line (2L) axicabtagene ciloleucel (axi-cel) versus standard of care (SOC) in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
- FL Locke (Author)
- J Chou (Author)
- S Vardhanabhuti (Author)
- R Perbost (Author)
- P Dreger (Author)
- BT Hill (Author)
- C Lee (Author)
- PL Zinzani (Author)
- N Kroeger (Author)
- A Lopez-Guillermo (Author)
- Hildegard Greinix (Author)
- WS Zhang (Author)
- G Tiwari (Author)
- CA To (Author)
- PC Cheng (Author)
- A Bot (Author)
- R Shen (Author)
- S Filosto (Author)
- J Galon (Author)
Activity: Talk, presentation or poster › Scientific talk or presentation › On site